JAGSNPHARM233.84

Jagsonpal Pharmaceuticals Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersAMRUTANJANNGLFINESYNCOMFHESTERBIOSIGACHILINCOLNWINDLASMcap ₹1,566 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations208.7268.7287.2293.8
Other Income9.38.212.012.0
Total Income218.0276.9299.2305.8
Expenses
+ Cost of Materials Consumed22.118.316.115.6
+ Purchases of Stock-in-Trade54.080.289.292.5
+ Changes in Inventories3.9-2.1-0.9-2.1
+ Employee Benefit Expense48.570.970.774.1
+ Finance Costs0.81.01.01.0
+ Depreciation & Amortisation1.78.19.49.2
+ Other Expenses57.250.354.052.6
Total Expenses188.1226.7239.6243.0
EBITDA23.151.158.161.1
EBIT21.442.948.651.9
Profit
PBT before Exceptional Items29.950.259.662.8
+ Exceptional Items0.019.7-2.1-2.1
Pretax Income29.969.957.560.8
+ Current Tax7.613.613.214.2
+ Deferred Tax-0.20.91.21.1
Tax Expense7.414.514.415.3
Net Income22.555.443.145.5
+ Net Income — Continuing Ops22.555.443.145.5
+ Other Comprehensive Income0.20.20.40.4
Total Comprehensive Income22.755.643.445.9
Per Share
Basic EPS8.498.266.406.80
Diluted EPS8.468.226.316.71
Other Comprehensive Income — detail
+ Other Comprehensive Income0.20.40.4
+ Items NOT to be Reclassified to P&L0.30.30.50.5
+ Tax on Items NOT to be Reclassified0.10.10.1
+ Tax on Items NOT to be Reclassified — alt tag0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations8.498.266.406.80
Diluted EPS — Continuing Operations8.468.226.316.71
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit128.7172.3182.9187.8
Gross Margin %61.6864.1163.6663.90
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)29.950.259.662.8
− Exceptional Items (reconciliation)0.019.7-2.1-2.1
Net Income Adj (tax-effected)22.539.844.647.0
EPS Adj8.495.936.637.03
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.002.002.002.00
Paid Up Equity Capital13.213.313.413.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.